Trending...
- Countryside Golf & Country Club general manager receives prestigious professional designation
- Better Together receives $15,000 from Gulf Coast Community Foundation to support hurricane relief
- Francesca Corbi Joins Coral Bay Recovery Clinical Team
MUNICH - Floridant -- OncoBeta® GmbH, a global medical device company specialising in innovative therapies for non-melanoma skin cancers (NMSCs), is supporting World Skin Cancer Awareness Month (May 2024) by focusing on educating patients suffering with NMSCs about the various treatment options currently available.
Global incidence continues to rise, with over 7.7 million cases of NMSC recorded annually.1 In response, the medical community is striving to enhance standard treatments and embrace new alternative approaches, enabling patients to personalise their care based on factors such as lesion localization, size, single or multiple lesions, age, other health conditions, and patient preference – all of which influence treatment selection. The overarching goal is to provide the optimal medical solution, achieve aesthetic outcomes, and prioritise a patient's quality of life.
Gerhard Dahlhoff, OncoBeta Medical Director, says, "Education is critical for addressing the rising rates of NMSCs globally, and knowing different treatment options available will hopefully alleviate the stress and anxiety surrounding a diagnosis. Treatments can impact your work life, home life or even retirement life but thanks to innovative treatment alternatives, you can now find the one that is effective and minimises the impact on your mental and physical wellbeing."
Laurie Leppard, residing in the Gold Coast, Australia, recently underwent treatment for a squamous cell carcinoma (SCC) situated on his left ear. Initial treatment options included surgery, risking disfigurement due to necessary cartilage removal, or radiation that would exacerbate his claustrophobia.
"Traditional radiation would've required me to wear a mask over my face during sessions, which was considerably daunting given my claustrophobia – especially as I would've needed more than 20 daily treatment visits," explains Laurie. "I really wasn't keen for surgery, and worries about more complications, so I made it my mission to research alternatives. When I discovered the newer rhenium-188 treatment – a mask-free, single-session, painless alternative without scarring – I jumped at it. Given that each clinic visit entails a 100km round trip, the single-session rhenium-188 treatment saved me considerable time, energy, discomfort, and disruption to my life."
Professor Julia Tietze, Dermatologist at Rostock University Hospital and author of recent study published in Clinical Nuclear Medicine, says, "I am able to discuss different treatment options with patients based on the size and depth of the lesion, also the location of the lesion, the medical history of the patient, the wishes of each individual considering their pain tolerance or ability to travel, and personal preference considering aesthetic outcomes or other factors."
In 2022, OncoBeta conducted research in Australia with over 1,200 people, to better understand attitudes towards skin health and treatment considerations. Australia has the highest incidence of recorded NMSCs, so this research provides valuable insights. The research asked patients diagnosed with NMSCs what factors they ranked highest: 97% said 'successful removal of the lesion' was extremely or very important. This was followed by 'fast recovery' (90%) then 'quick and easy procedure' (88%). More than three quarters of NMSC patients said a 'painless' procedure was extremely or very important (77%), followed by 'good aesthetic results' (76%) and 'non-invasive' (73%).2 §
More on The Floridant
"From my own experience treating patients with NMSCs, I can say that we of course want to remove the entire lesion in one session, but patients are increasingly more concerned about the cosmetic outcome and highlighting their personal situation – such as claustrophobia or anxiety about some treatments," says Prof. Tietze.
The same research found that 81% of patients were treated surgically or with a combination of surgery and non-surgical treatments, however most respondents stated that it was extremely or very important for their treatment to be painless, non-invasive and provide good aesthetic results.2
Mainstay treatments for NMSC include surgery, radiotherapy, cryotherapy and now epidermal radioisotope therapy, a procedure utilising the beta emitter radioisotope, rhenium-188:
"We do have patients who just do not want to have surgery – most of the time, again – because most of the time it's not their first lesion and they know exactly what to expect with surgery, and they just don't want to do that again," adds Prof. Tietze. "Especially the older patients, because as everyone knows the incidence of NMSC is increasing among the older population, but they're not always willing to do something painful… so it's really nice to have an option to treat those patients."
More on The Floridant
Early detection is key for treating skin cancer. World Skin Cancer Awareness Month offers key education about NMSCs and is an important reminder for people to regularly get their skin checked by a health professional. Ignoring a change in the skin or avoiding having it checked and monitored by a health professional means it may grow and/or spread to other parts of the body, or in the worst case it may become life-threatening.
OncoBeta's Skin Cancer Treatment Awareness Month campaign is encouraging everyone to visit a GP, dermatologist, or other skin health specialist to inspect any changes to their skin, and if necessary to learn about ALL treatments that are available.
Find out more about treatment alternatives, visit: www.spotdetective.com
About OncoBeta®
OncoBeta®, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s), and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.
Find out more about the Rhenium-SCT® at www.oncobeta.com
Follow us on social media:
LinkedIn: www.linkedin.com/company/oncobeta-gmbh/
Facebook: www.facebook.com/oncobeta/
Instagram: www.instagram.com/oncobeta_gmbh/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties, and other factors, many of which are outside of OncoBeta's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
*Complete tumour regression in 98.5% of lesions treated.
†No pain reported during procedure.
‡A procedure is considered non-invasive when no break or cut in the skin is created.8
§OncoBeta's research was conducted in November 2022 and surveyed a sample of 1,235 people aged 18 and above. OmniPoll post-weighted the results to the Australian Bureau of Statistics census data reflecting Australian's overall population and providing statistically reliable insights.
References:
Global incidence continues to rise, with over 7.7 million cases of NMSC recorded annually.1 In response, the medical community is striving to enhance standard treatments and embrace new alternative approaches, enabling patients to personalise their care based on factors such as lesion localization, size, single or multiple lesions, age, other health conditions, and patient preference – all of which influence treatment selection. The overarching goal is to provide the optimal medical solution, achieve aesthetic outcomes, and prioritise a patient's quality of life.
Gerhard Dahlhoff, OncoBeta Medical Director, says, "Education is critical for addressing the rising rates of NMSCs globally, and knowing different treatment options available will hopefully alleviate the stress and anxiety surrounding a diagnosis. Treatments can impact your work life, home life or even retirement life but thanks to innovative treatment alternatives, you can now find the one that is effective and minimises the impact on your mental and physical wellbeing."
Laurie Leppard, residing in the Gold Coast, Australia, recently underwent treatment for a squamous cell carcinoma (SCC) situated on his left ear. Initial treatment options included surgery, risking disfigurement due to necessary cartilage removal, or radiation that would exacerbate his claustrophobia.
"Traditional radiation would've required me to wear a mask over my face during sessions, which was considerably daunting given my claustrophobia – especially as I would've needed more than 20 daily treatment visits," explains Laurie. "I really wasn't keen for surgery, and worries about more complications, so I made it my mission to research alternatives. When I discovered the newer rhenium-188 treatment – a mask-free, single-session, painless alternative without scarring – I jumped at it. Given that each clinic visit entails a 100km round trip, the single-session rhenium-188 treatment saved me considerable time, energy, discomfort, and disruption to my life."
Professor Julia Tietze, Dermatologist at Rostock University Hospital and author of recent study published in Clinical Nuclear Medicine, says, "I am able to discuss different treatment options with patients based on the size and depth of the lesion, also the location of the lesion, the medical history of the patient, the wishes of each individual considering their pain tolerance or ability to travel, and personal preference considering aesthetic outcomes or other factors."
In 2022, OncoBeta conducted research in Australia with over 1,200 people, to better understand attitudes towards skin health and treatment considerations. Australia has the highest incidence of recorded NMSCs, so this research provides valuable insights. The research asked patients diagnosed with NMSCs what factors they ranked highest: 97% said 'successful removal of the lesion' was extremely or very important. This was followed by 'fast recovery' (90%) then 'quick and easy procedure' (88%). More than three quarters of NMSC patients said a 'painless' procedure was extremely or very important (77%), followed by 'good aesthetic results' (76%) and 'non-invasive' (73%).2 §
More on The Floridant
- Shoe Elegance Relaunches as an Online Boutique, Reviving Timeless Style and Sophistication
- CULTURE & COCKTAILS At The Ben Returns on Jan 6 with Award-Winning Comedy Writer ALAN ZWEIBEL
- Naughty Nevada Band Launches a Bold New Website Design
- Inspiring the Full Arch Industry: Dr. James Fetsch Speaks At The Full Arch Growth Conference 2024
- BHRT Training Academy Announces inaugural BHRT 'Symposium at Sea 2025' for Healthcare Providers
"From my own experience treating patients with NMSCs, I can say that we of course want to remove the entire lesion in one session, but patients are increasingly more concerned about the cosmetic outcome and highlighting their personal situation – such as claustrophobia or anxiety about some treatments," says Prof. Tietze.
The same research found that 81% of patients were treated surgically or with a combination of surgery and non-surgical treatments, however most respondents stated that it was extremely or very important for their treatment to be painless, non-invasive and provide good aesthetic results.2
Mainstay treatments for NMSC include surgery, radiotherapy, cryotherapy and now epidermal radioisotope therapy, a procedure utilising the beta emitter radioisotope, rhenium-188:
- Surgery is a common treatment option for non-melanoma skin cancer; in particular 'Mohs' surgery. This is an invasive procedure to remove the cancer in several steps. First, a thin layer of tissue is removed. Then, a second thin layer of tissue is removed and viewed under a microscope to check for cancer cells. Layers are removed one at a time until the tissue viewed under a microscope shows no remaining cancer.
- Electrodessication and curettage is an option for some non-melanoma skin cancers. The doctor scoops out the cancer with a small, spoon-shaped instrument, then seals the wound and destroys any remaining cancer cells using heat.
- External beam radiation is sometimes used instead of surgery, especially for large NMSCs or for people who are not well enough to have surgery.3,4 It uses electron or photon beams to kill the cancer cells.
- Light-based treatment may be recommended for early-stage NMSCs. For 2-3 weeks the skin is prepared by applying cream or ointment daily. Then the doctor places you under an LED phototherapy lamp. This provokes an immune reaction by your body which kills the skin cancer. The process may or may not be painful.
- Cryotherapy (freezing) can be used for small, shallow skin cancers. After applying an anaesthetic, the doctor uses liquid nitrogen to freeze the cancer and destroy the cells. A blister or sore may form which heals, revealing healthy skin. Reduced skin pigmentation may occur.
- Topical treatment, a chemotherapy cream can be applied to the skin for a period of time, for treatment of Bowen's disease – a mild, slow-growing type of skin cancer. Burning, redness and sores may occur.
- Rhenium-SCT is a localised radiation therapy that uses the rhenium-188 isotope which is applied as a paste directly to the lesion – it is a single session* lasting 45 to 180 minutes.5-7 It is painless6,7† and non-invasive6‡. A crust or scab forms that may become itchy. Rhenium-188 therapy leaves no scar but the skin may appear lighter.
"We do have patients who just do not want to have surgery – most of the time, again – because most of the time it's not their first lesion and they know exactly what to expect with surgery, and they just don't want to do that again," adds Prof. Tietze. "Especially the older patients, because as everyone knows the incidence of NMSC is increasing among the older population, but they're not always willing to do something painful… so it's really nice to have an option to treat those patients."
More on The Floridant
- 3Li: Revolutionizing Lithium Trading with Blockchain Technology
- The Score Album for "The Lost Weekend: A Love Story" Released Today
- Pet Professional Guild Announces Corporate Partnership with The Muzzle Movement
- Youth Group Makes History as First Visitors to National Electronics Museum
- Pololikashvili runs for re-election as UN Tourism Secretary General for 2026-2029 term
Early detection is key for treating skin cancer. World Skin Cancer Awareness Month offers key education about NMSCs and is an important reminder for people to regularly get their skin checked by a health professional. Ignoring a change in the skin or avoiding having it checked and monitored by a health professional means it may grow and/or spread to other parts of the body, or in the worst case it may become life-threatening.
OncoBeta's Skin Cancer Treatment Awareness Month campaign is encouraging everyone to visit a GP, dermatologist, or other skin health specialist to inspect any changes to their skin, and if necessary to learn about ALL treatments that are available.
Find out more about treatment alternatives, visit: www.spotdetective.com
About OncoBeta®
OncoBeta®, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s), and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.
Find out more about the Rhenium-SCT® at www.oncobeta.com
Follow us on social media:
LinkedIn: www.linkedin.com/company/oncobeta-gmbh/
Facebook: www.facebook.com/oncobeta/
Instagram: www.instagram.com/oncobeta_gmbh/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties, and other factors, many of which are outside of OncoBeta's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
*Complete tumour regression in 98.5% of lesions treated.
†No pain reported during procedure.
‡A procedure is considered non-invasive when no break or cut in the skin is created.8
§OncoBeta's research was conducted in November 2022 and surveyed a sample of 1,235 people aged 18 and above. OmniPoll post-weighted the results to the Australian Bureau of Statistics census data reflecting Australian's overall population and providing statistically reliable insights.
References:
- Global Burden of Disease Cancer Collaboration, et al. JAMA Oncol. 2019;5(12):1749-1768.
- OmniPoll Survey November 2022.
- Radiation therapy for skin cancer. Available at: https://www.cancercouncil.com.au/skin-cancer/treatment/radiotherapy/ (Accessed March 2024).
- Radiation therapy for basal and squamous cell skin cancers. Available at https://www.cancer.org/cancer/basal-and-squamous-cell-skin-cancer/treating/radiation-therapy.html (Accessed March 2024].
- Castellucci P, et al. Eur J Nucl Med Mol Imaging. 2021;48(5):1511-1521.
- Cipriani C, et al. J Dermatol Treat. 2022;33(2):969–975. Epub 22 Jul 2020.
- Data on file. OncoBeta, Garching, Germany.
- Australian Therapeutic Goods Administration ARTG Public summary 400142.
Source: OncoBeta GmbH
0 Comments
Latest on The Floridant
- The Florida Forum Speaker Series to Welcome Deepak Chopra
- Tommy Bohanon Foundation collects 600 toys, raises $20,000 at 2024 Softball Tournament
- Project Astral NFT Drop by AI Film Guerrillas Released via Ethereum on Base Network
- Dr. Sathish Palayam Speaks at the Full Arch Growth Conference, Sharing Insights to Revolutionize Patient Care!
- InStockRx Wins 1871 Supply Chain Pitch, Announces GS1 Partnership
- Donors and Recipients of Nashville Chopin's Metro School Piano Donation Program Announced
- WPB's Mounts Botanical Garden is Offering Two Special Yuletide Events This Month
- International Dreams Come True for Southwest Florida Artists Roland Ruocco and Wendy White!
- Loyal American Airlines Passenger and Son of 33-Year Employee Files Legal Action Against Airline for Racial Bias, Unlawful Ban, and Injustice
- Army vs Navy Tailgate Party & Fundraiser
- Movieboost.ai: The Future Of Film Marketing And Automation
- OneSolution® Dental Implant Centers Offers Advanced Zygomatic Dental Implant Solutions
- Magazine features Pink and Main in its December issue
- Unbeatable Value Sponsorship Opportunity Announced for Love Eat Travel Series on PBS
- Kuruma Imports Hosting Toys For Tots Car Meet to Spread Holiday Cheer
- Francesca Corbi Joins Coral Bay Recovery Clinical Team
- "Transform Your Look with Expert Hair, Skin, and Beauty Services at McAllister Spa!"
- Security Experts to Host Conference on Deepfakes and Cybersecurity in 2025
- Pittsburgh Professional Women invites all Women and Allies to MONEY CLUB
- Speranza Dental Implant Center's New Website Launch!